The US Food and Drug Administration (FDA) has granted Pfizer subsidiary Wyeth Pharmaceuticals approval of its Trumenba vaccine for the prevention of meningococcal disease caused by Neisseria meningitidis serogroup B in people ages 10 to 25, the first of its kind in the US. Previously the only meningococcal vaccines licensed in the US covered four of the five main disease-causing serogroups: A, C, Y and W. Another serogroup B vaccine, Novartis' Bexsero, was approved by the EU in January 2013 and is available in 34 countries. Trumenda was approved less than six months after Wyeth's submission under the FDA's breakthrough therapy program.